Third Pole Therapeutics
David Zapol has a diverse work experience spanning various companies and roles. David is currently the Co-Founder of Goodlife Clinic (Ivuriro) since March 2022. Prior to that, they were the Co-Founder and Strategic Advisor at Arrive Bio since December 2019. Before that, they held multiple positions at Third Pole Therapeutics, including Co-Founder and Strategic Advisor from October 2019 to present, and CEO from July 2014 to October 2019. David was also the Co-Founder, founding COO, and Strategic Advisor at Goodlife - Pharmacy Health and Beauty from August 2012 to February 2022. Earlier in their career, they worked as a Director at FSG from January 2006 to June 2012. David also served as an MBA Intern at the Earth Institute at Columbia University in 2005 and as a Summer Fellow and Consultant at Investors Circle Foundation from June 2004 to January 2006. David's experience also includes a role as Director of Marketing at Pharsight Corporation from January 2001 to January 2002 and Co-Founder and VP of Product Development at Metazoa Systems from January 1999 to January 2001.
David Zapol attended Massachusetts Institute of Technology from 1990 to 1995, where they pursued a degree in Biology and graduated with an SB degree. Following this, from 1995 to 1997, they attended Stanford University School of Medicine and obtained a Masters in Science with a specialization in Immunology. Later on, from 2003 to 2005, David Zapol went to Columbia Business School, where they earned an MBA/MPH degree in Business and Public Health.
This person is not in any teams
Third Pole Therapeutics
Third Pole, Inc. is a US-based company developing next generation life-saving cardiopulmonary therapies. We are building on our team’s legacy in inhaled nitric oxide (NO), the current standard of care, to develop next generation life-saving heart and lung therapies. Our first product is being designed to be a simple, convenient, economical, and lightweight device capable of generating nitric oxide from air on-demand and on-site which potentially eliminates the need for large compressed gas cylinders. We believe our novel approach of creating NO on demand has the promise to create new markets by enabling the worldwide use of inhaled NO in settings outside of acute care.